Author:
Kadono Yoshifumi,Miwa Sotaro,Shima Takashi,Konaka Hiroyuki,Mizokami Atsushi,Yotsuyanagi Satoshi,Hirata Akio,Takase Yasukazu,Sugata Toshiaki,Shimamura Masayoshi,Namiki Mikio
Publisher
Biomedical Research Press
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference19 articles.
1. 1. Akaza H, Tsukamoto T, Murai M, Nakajima K and Naito S (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37, 755-762.
2. 2. Bellmunt J and Guix M (2009) The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int 103, 572-577.
3. 3. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, Philip T and Favrot M (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52, 3317-3322.
4. Nomenclature of the Human Interferon Genesa
5. 5. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A and Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103-2111.